Zibotentan (ZD4054)

Modify Date: 2025-08-20 18:13:15

Zibotentan (ZD4054) structure	Common Name	Zibotentan (ZD4054)
	CAS Number	186497-07-4	Molecular Weight	424.433
	Density	1.4±0.1 g/cm3	Boiling Point	637.0±65.0 °C at 760 mmHg
	Molecular Formula	C₁₉H₁₆N₆O₄S	Melting Point	N/A
	MSDS	Chinese USA	Flash Point	339.0±34.3 °C
	Symbol	GHS07	Signal Word	Warning

Use of Zibotentan (ZD4054)

Zibotentan (ZD4054) is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). IC50 value: 21 nM Target: ETA receptorZibotentan is capable of inhibiting or reducing the multitude of effects that are evoked by ET-1 activation of the ETA receptor and which promote tumor survival, growth and progression. Zibotentan (ZD4054) treatment produced significant inhibition of tumor growth in ovarian and breast xenografts.

Name	N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
Synonym	More Synonyms

Description	Zibotentan (ZD4054) is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM). IC50 value: 21 nM Target: ETA receptorZibotentan is capable of inhibiting or reducing the multitude of effects that are evoked by ET-1 activation of the ETA receptor and which promote tumor survival, growth and progression. Zibotentan (ZD4054) treatment produced significant inhibition of tumor growth in ovarian and breast xenografts.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Endothelin Receptor Research Areas >> Cancer
References	[1]. Zibotentan James, N.D., Growcott, J.W. Drugs Fut 2009, 34(8): 624. [2]. Clarkson-Jones JA, Kenyon AS, Kemp J, Lenz EM, Oliver SD, Swaisland H.,Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.,Xenobiotica. 2012 Apr;42(4):363-71. Epub 2011 Oct 20. [3]. Li J, Liu Y, Qian J, Wu L, Kemp J, Nii M, Tomkinson H, Zuo Y, Ranson M, Usami M.,Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.,Cancer Chemother Pharmacol. 2012 Jul;70( [4]. Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.,Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. ,Cancer [5]. Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T.,Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.,BMC Clin Pharmacol. 2011 Mar 17;11:3.

Description

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Endothelin Receptor

Research Areas >> Cancer

References

[1]. Zibotentan James, N.D., Growcott, J.W. Drugs Fut 2009, 34(8): 624.

[2]. Clarkson-Jones JA, Kenyon AS, Kemp J, Lenz EM, Oliver SD, Swaisland H.,Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.,Xenobiotica. 2012 Apr;42(4):363-71. Epub 2011 Oct 20.

[3]. Li J, Liu Y, Qian J, Wu L, Kemp J, Nii M, Tomkinson H, Zuo Y, Ranson M, Usami M.,Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.,Cancer Chemother Pharmacol. 2012 Jul;70(

[4]. Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.,Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. ,Cancer

[5]. Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T.,Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.,BMC Clin Pharmacol. 2011 Mar 17;11:3.

Density	1.4±0.1 g/cm3
Boiling Point	637.0±65.0 °C at 760 mmHg
Molecular Formula	C₁₉H₁₆N₆O₄S
Molecular Weight	424.433
Flash Point	339.0±34.3 °C
Exact Mass	424.095367
PSA	141.37000
LogP	2.38
Vapour Pressure	0.0±1.9 mmHg at 25°C
Index of Refraction	1.628
InChIKey	FJHHZXWJVIEFGJ-UHFFFAOYSA-N
SMILES	COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1
Storage condition	-20°C

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Precautionary Statements	P301 + P312 + P330
RIDADR	NONH for all modes of transport
RTECS	UT7937700

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Schelman WR et al

Invest. New Drugs 29(1) , 118-25, (2011)

N-(3-Methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide

Zd 4054

S1456_Selleck

ZD4054

Zibotentan

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Zibotentan (ZD4054)
Price: Check
Purity: 98.0%
Delivery: 10 Day
Contact: Yang
Email: sales@echemcloud.com

DC Chemicals Limited
China
Product Name: Zibotentan（ZD4054）
Price: $550.0/100mg $950.0/250mg $1900.0/1g
Purity: 98.0%
Delivery: 3 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

ShangHai DC Chemicals Co.,Ltd
China
Product Name: Zibotentan（ZD4054）
Price: ￥Inquiry/1g
Purity: 98.9%
Delivery: 1 Day
Contact: Tony Lai
Email: order@dcchemicals.com

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: ZIBOTENTAN(ZD4054)
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Delivery: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

Get all suppliers and price by the below link:

Zibotentan (ZD4054) suppliers

Price: $185/10mM*1mLinDMSO

Reference only. check more Zibotentan (ZD4054) price

Zibotentan (ZD4054)

Use of Zibotentan (ZD4054)

Names

Zibotentan (ZD4054) Biological Activity

Chemical & Physical Properties

Safety Information

Articles1

Synonyms

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.